Rate of response to CyBorD is ‘truly remarkable’

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 12
Volume 17
Issue 12

There was a very rapid response [to CyBorD], which has been typical when you incorporate bortezomib into the initial regimens,” commented Dr. Anderson, from the Dana-Farber Cancer Institute in Boston.

There was a very rapid response [to CyBorD], which has been typical when you incorporate bortezomib into the initial regimens,” commented Dr. Anderson, from the Dana-Farber Cancer Institute in Boston.

“As is 100% of the time true, as far as I know, the adverse cytogenetics- del(13) and t(4;14)-are no longer relevant in the context of bortezomib- containing initial therapies.” The rate of complete or near-complete response increased from 39% to 46% to 72%, going from the intent-to-treat population to patients who completed treatment to transplant recipients, Dr. Anderson observed, characterizing the rates achieved as “truly remarkable.”

“I believe this is another example of a very active bortezomib-containing new therapy,” he said.

 

The main article can be found here:
CyBorD combo supports stem cell collection in newly diagnosed multiple myeloma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts in this video
2 experts in this video
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
2 experts are featured in this series.
Related Content